Category Archives: EP

This growing area will cover the management of arrhythmias and their complications.

Duke Cardiology Grand Rounds: evolution of the ICD

We were delighted to have Duke alum Dr. Gust Bardy visit with us last week. He has previously helped conduct the landmark Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).  His work with implantable defibrillators has continued wtih the development of an entirely subcutaneous ICD.  He presented the fascinating story of its development last week at Duke Cardiology Grand Rounds.

Tracking performance, improving quality, advancing research

US-based clinical registries, such as the National Cardiovascular Data Registry and Get With The Guidelines, have been instrumental in identifying and addressing gaps in quality of care for patients across the country. It is fascinating to see approaches in other countries who have developed nationwide clinical registries, inclusive of all citizens. In Sweden, clinical registries like SCAAR and SWEDEHEART, have not only been used to describe trends in nationwide clinical outcomes but are now being used as a platform for the conduct of randomized trials. With rich characterization of patients and longitudinal followup, clinical registries can be used to identify, enroll, and follow patients randomized to treatments or strategies of care that need more investigation. These innovative “randomized clinical registry studies” are being conducted in the US as well. We need more of them.


Dr. Kenneth Mahaffey presented the eagerly awaited results from ROCKET AF, which showed that the new oral factor Xa inhibitor rivaroxaban met its primary efficacy end point of noninferiority to dose-adjusted warfarin with regard to all-cause stroke and non-central nervous system systemic embolism.  Again, this was a packed session as you can see below.

Dr. Mahaffey presents the results of ROCKET AF

Dr. Mahaffey convenes with Drs. Rob Califf and Manesh Patel aftewards

Here are the ROCKET-AF slides presented by Dr. Mahaffey.

Dr. Manesh Patel presented the findings at the "Meet the Trialists" session.

A large crowd gathered to hear the results in detail.